Novartis investigational bronchodilator QAB149 compared to tiotropium
- Details
- Category: Novartis
Novartis has announced results from Phase III trials showing QAB149 (indacaterol), an investigational once-daily bronchodilator for chronic obstructive pulmonary disease (COPD), significantly improves lung function[3] and provides a significant reduction in breathlessness[1] compared to tiotropium, a current treatment option.
Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) has announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court's decision that Roche's peg-EPO product, Mircera, infringes four Amgen patents ('868, '698, '933 and '422) relating to recombinant erythropoietin (EPO) and processes for making it.
Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has unveiled a new operating model and announced a series of changes to speed medicines from its pipeline to patients. To help achieve this goal, the company will establish a Development Center of Excellence to streamline and accelerate late-stage development of new medicines, and will reorganize its pharmaceutical business into four business units that will operate alongside the Elanco animal health business unit.
Two new studies report increased survival rates in Tamiflu-treated patients
- Details
- Category: Roche
Tamiflu (oseltamivir) demonstrated significantly improved survival rates in patients with the highly pathogenic H5N1 influenza (avian flu) and severe cases of seasonal influenza, according to two new studies presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.(1,2)
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China.
New data show patients with chronic low back pain maintained pain reduction on duloxetine
- Details
- Category: Boehringer Ingelheim
New data show patients with chronic low back pain on duloxetine hydrochloride (Cymbalta®) maintained reductions in pain for 41 weeks.(1) In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.(1)
Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced a definitive agreement to acquire the outstanding equity of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of cardiac mitral valves. The acquisition provides Abbott with a presence in the growing area of non-surgical treatment for structural heart disease, in which physicians use catheter-based devices to repair or replace basic structural components of the heart such as mitral and aortic valves.
More Pharma News ...
- FDA Advisory Committee makes favorable recommendation for Cervarix
- Online Video Library Launched To Share Martha Beck's Experience Living with Fibromyalgia
- Abbott Again Named One of the 'Best Places to Launch a Career' by BusinessWeek
- Shantha Biotechnics Awarded Large Vaccine Contracts by United Nations Agency
- Roche recognised as new Super Sector Leader in Dow Jones Sustainability Index
- Novartis MF59® vaccine shows strong immune response in A(H1N1) clinical trials
- Abbott to Acquire Visiogen, Expanding Vision Care Portfolio